How are my fat cells handled for autologous treatment?
Stem Cell Mexico does not perform autologous fat-derived cell treatments. We use only allogeneic mesenchymal stromal cells (MSCs) derived from Wharton's jelly, the connective tissue of donated umbilical cords, so no fat or bone marrow is ever collected from our patients.
Because many people research this option, this guide explains how autologous fat cells are handled in clinics that offer them. In those settings, the fat tissue follows a controlled chain of steps: it is collected through a small liposuction procedure under sterile conditions, labeled and transported under controlled temperature to a certified cell processing laboratory, and then processed either the same day into a stromal vascular fraction (SVF) or over several weeks into culture-expanded adipose-derived stromal cells (ADSCs). Before any cells are returned to you, the laboratory performs quality and safety checks that typically include cell viability testing, sterility and contamination testing, and serological (infectious disease) screening, with every step documented and traceable to you.
This guide explains each step, the difference between SVF and expanded cells, what safety testing involves, and why Stem Cell Mexico chose to work exclusively with Wharton's jelly MSCs instead.
Why some patients consider their own fat cells
Fat tissue (adipose tissue) contains a relatively high number of mesenchymal stromal cells compared with bone marrow, and it can be collected with a minimally invasive procedure. Some patients prefer autologous cells because they come from their own body, which avoids any donor-related immune response. Autologous fat-derived cells are also widely used in reconstructive and aesthetic surgery, such as enriched fat grafting.
Step 1: Medical evaluation and pre-procedure testing
Before harvesting, the doctor confirms that autologous cells are appropriate for your condition and that you are a suitable candidate for liposuction. This includes:
- Medical history, medications (especially blood thinners) and allergies.
- Blood tests, including a blood count and infectious disease screening (such as HIV, hepatitis B and C), which are required for handling human tissue safely in the laboratory.
- An assessment of donor sites with enough fat, usually the abdomen or flanks.
Step 2: Fat collection (mini-liposuction)
Under local anesthesia, sometimes with mild sedation, a small amount of fat is removed through tiny incisions using a thin cannula. The volume depends on the protocol, often from about 50 to several hundred milliliters. The procedure is performed under sterile conditions, and the sample is immediately placed in a sterile, sealed container.
Recovery at the harvest site usually involves mild soreness, swelling and bruising for several days. A compression garment may be recommended.
Step 3: Labeling, chain of custody and transport
Each sample is labeled with unique identifiers linking it to you. It is transported in temperature-controlled packaging to the processing laboratory, with documentation of collection time, handling and receipt. This chain of custody ensures that the cells you receive are your own and that conditions were controlled throughout.
Step 4: Processing, two very different options
Option A: Same-day stromal vascular fraction (SVF)
The fat is washed and, in many protocols, treated with enzymes (such as collagenase) to break down the tissue. Centrifugation then separates a cell-rich pellet called the SVF. SVF is a mixture of cells: MSC-like progenitor cells, blood vessel cells, immune cells and others. It is ready within hours.
- Advantages: no culture time, a single visit.
- Limitations: the number of MSCs varies between patients, the product is a mixed population, and characterization is limited.
Option B: Culture-expanded adipose-derived stromal cells (ADSCs)
Cells are isolated from the fat and grown in a laboratory under controlled conditions until they reach a target number. This usually takes several weeks, and cells may be stored until treatment.
- Advantages: a defined, characterized cell population at a target dose.
- Limitations: requires a second visit, laboratory time and higher cost, and expansion of autologous cells from older or less healthy patients may be slower.
Step 5: Quality control and safety testing
Before cells are released for treatment, a certified laboratory typically performs:
- Cell count and viability: how many cells are present and what percentage are alive.
- Sterility testing: checking for bacteria and fungi.
- Endotoxin and, for expanded products, mycoplasma testing.
- Serological testing: confirming infectious disease screening results.
- Identity testing for expanded products: confirming MSC surface markers according to international criteria.
- Documentation and traceability: recording every step and result.
Only after these checks are completed are the cells released for application.
Step 6: Storage and return
Same-day SVF is applied within hours. Expanded cells may be cryopreserved (frozen with protective agents) until your treatment date, then thawed and tested for viability before application. The cells are then applied according to your plan, for example by ultrasound-guided injection into a joint or by another route your doctor recommends.
Factors that influence the quality of your own fat cells
The quality of autologous cells reflects the health of the person they come from. Studies have shown that age, obesity, diabetes, smoking and chronic inflammation can reduce the number of stromal cells in fat and affect how well they grow and function. The harvest site and technique also matter: gentle collection with appropriate cannulas helps preserve cell viability, and delays or temperature changes during transport can reduce it. Certain medications, including some that affect the immune system, may also influence results. This does not mean autologous cells cannot work for older adults or people with health conditions, but it explains why yields vary and why laboratories measure cell numbers and viability before treatment. These variations are one of the reasons Stem Cell Mexico works only with donor cells from Wharton's jelly, whose quality does not depend on the patient's age or health.
What the evidence says
Safety: A comprehensive 2026 literature review in Stem Cell Research & Therapy (Nonnarath and Serratrice) analyzed the clinical use of autologous SVF across many applications. Adverse events were mostly mild and procedure-related, such as temporary pain, swelling or local inflammation, and serious complications like embolism, infection or tumor formation were not reported in the cases reviewed. However, the authors highlighted important limitations: small and heterogeneous studies, non-randomized designs, variable preparation methods and short follow-up, and they called for large randomized trials and long-term monitoring.
Effectiveness: Studies in knee osteoarthritis and other conditions report improvements in pain and function in some patients, but variability in preparation and dosing makes it difficult to compare results or establish consistent benefit.
Regulatory context
Regulation of fat-derived cell products depends heavily on how they are processed:
- The U.S. Food and Drug Administration (FDA) guidance on minimal manipulation and homologous use explains that products that are more than minimally manipulated, or used for a different function than in the original tissue, are regulated as biological drugs that require approval.
- In 2021, the U.S. Court of Appeals for the Eleventh Circuit, in United States v. U.S. Stem Cell Clinic, held that SVF produced by enzymatically processing fat was no longer the same tissue removed from the patient and was therefore an unapproved drug.
- In Mexico, establishments that collect, process or apply stem cells require a sanitary license from COFEPRIS, and processing laboratories must meet established standards.
Autologous fat cells versus donor umbilical cord cells
| Factor | Autologous fat-derived | Donor umbilical cord (Wharton's jelly) |
|---|---|---|
| Harvest procedure | Liposuction required | None |
| Cell age | Same as patient | Newborn tissue |
| Dose control | Variable (SVF) or defined (expanded) | Defined |
| Timing | Same day (SVF) or weeks (expanded) | Prepared for your date |
| Immune response to donor | None | Low; no matching required |
For many patients, especially older adults, people with chronic conditions or those taking blood thinners, donor umbilical cord cells offer clear practical advantages.
Why Stem Cell Mexico uses only Wharton's jelly MSCs
We decided to work with a single, well-characterized cell product rather than offering several cell sources. Wharton's jelly MSCs come from young, healthy newborn tissue donated after full-term births, so their quality does not depend on your age, weight, diabetes or other conditions. They are expanded in a licensed laboratory to the exact dose your doctor prescribes, with quality and safety testing before release. You avoid liposuction or bone marrow aspiration, with their pain, bruising, recovery and small risk of bleeding or infection at the harvest site, and you avoid waiting weeks for your own cells to be expanded. Working with one consistent product also allows our medical team to apply standardized protocols and compare results more reliably across patients.
Risks and limitations
In clinics that offer autologous fat treatments, liposuction can cause pain, bruising, swelling, numbness and, rarely, infection, bleeding or contour irregularities at the harvest site, and the main limitations are variability in cell yield and quality and limited high-quality evidence. With donor Wharton's jelly MSCs, there is no harvest-site risk; the most common effects are temporary soreness at injection sites and, after intravenous infusions, mild fever or fatigue, and rare risks include infection and allergic reactions.
Questions to ask during your evaluation
- Why are donor Wharton's jelly MSCs recommended for my condition?
- How many cells will I receive, and how is that dose chosen?
- How do donor cells compare with the autologous options I have read about?
- What evidence supports this treatment for my condition?
Bottom line
Autologous fat cells are collected by mini-liposuction, transported under a documented chain of custody and processed by a certified laboratory either as same-day SVF or as expanded cells, with viability, sterility and infectious disease testing before release. Stem Cell Mexico does not offer autologous fat treatments; we use only donor MSCs from Wharton's jelly, which avoid any harvesting procedure and come from a tested, documented batch. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your condition, goals and medical history.
References
- U.S. Food and Drug Administration (FDA): Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use (guidance) (opens in a new tab)
- U.S. Court of Appeals for the Eleventh Circuit: United States v. U.S. Stem Cell Clinic, LLC, No. 19-13276 (2021) (opens in a new tab)
- Nonnarath C, Serratrice N. Safety profile of autologous adipose-derived stromal vascular fraction in clinical use: an exhaustive literature review. Stem Cell Research & Therapy, 2026 (opens in a new tab)
